INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2014 | $3,714,000 | -53.9% | 15,700 | -53.9% | 0.20% | -57.4% |
| Q2 2014 | $8,057,000 | -54.5% | 34,050 | -36.5% | 0.47% | -53.9% |
| Q1 2014 | $17,692,000 | +56.9% | 53,650 | -67.5% | 1.02% | +55.7% |
| Q4 2013 | $11,279,000 | +144.6% | 165,200 | +147.3% | 0.66% | +115.4% |
| Q3 2013 | $4,612,000 | – | 66,800 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |